The pain-reliever acetaminophen (also known as paracetomol) is one of the best-selling over-the-counter medications, used by more than 200 million Americans a year. It is sold under many brand names, including Tylenol, and is an ingredient in nearly 200 medications, both over-the-counter (such as Excedrin, Midol, NyQuil, and Sudafed) and prescription (such as Vicodin).
Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.
Cataldo Doria, M.D., Ph.D., Nicoletti Family Professor of Transplant Surgery at Jefferson Medical College of Thomas Jefferson University, and director of the Division of Transplantation at Thomas Jefferson University Hospital is the first transplant surgeon in the United States to use a new totally artificial liver assist device as a bridge to transplantation.
Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.
Bayer Diabetes Care today announced the introduction of the DIDGET™ blood glucose monitoring system in the United States. The DIDGET meter is unique because it is the only blood glucose meter that connects directly to Nintendo DS™ and DS Lite gaming systems to help kids manage a lifelong disease by rewarding them for building consistent testing habits and meeting personalized blood glucose target ranges. Bayer's DIDGET meter is now available for purchase in the U.S. through CVS.com, Drugstore.com and Walgreens.com.
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City
Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.
Cadence Pharmaceuticals, Inc. announced today that, based on feedback received during a meeting with the U.S. Food and Drug Administration on April 16, 2010, it plans to re-submit a New Drug Application for its investigational product candidate, OFIRMEV (acetaminophen) injection, within the next 30 days.
Patients need help to navigate the health care system and to better manage their own chronic health conditions. New health care delivery models that effectively provide those services have been shown to both lower overall costs and improve patient health.
Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.
Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.
Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena.
A nationwide survey of business executives by Crain Communications Inc about the recent federal health care reform law has found that a majority of U.S. employers are unlikely to cease offering health care benefits to their workers.
Arbor Pharmaceuticals, a specialty pharmaceutical company focused on pediatric medicine, announced today that an investment group led by Jason Wild of JW Asset Management, LLC and Edward Schutter has acquired the company.
There are millions of vacation destinations to visit this summer and thousands of sights to see, but there is one surefire way to ruin your trip -- getting sick. Although you may not be thinking about viruses and bacterial infections when you plan your trip, there are a few nasty bugs you should be aware of as you pack your bags.
Labopharm Inc. today announced its wholly owned subsidiary, Labopharm Europe Limited, has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co., Ltd. of Japan.
NeurogesX, Inc. announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia, the nerve pain that can occur after shingles.
Cumberland Pharmaceuticals Inc. has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure. Acetadote was launched by Cumberland in 2004 as the first U.S.-approved injectable drug to treat acetaminophen overdose.
Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer.
When pain from increased physical activity doesn’t go away in a couple of days, the cause could be a stress fracture. The March issue of Mayo Clinic Health Letter covers these tiny, partial bone fractures, why they occur and how they are treated.
Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.